Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study.

Autor: Leo P; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA., Janowczyk A; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.; Department of Oncology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland., Elliott R; Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Janaki N; Department of Pathology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA., Bera K; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA., Shiradkar R; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA., Farré X; Public Health Agency of Catalonia, Lleida, Catalonia, Spain., Fu P; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA., El-Fahmawi A; Department of Urology, Penn Presbyterian Medical Center, Philadelphia, PA, USA., Shahait M; Department of Urology, Penn Presbyterian Medical Center, Philadelphia, PA, USA., Kim J; Department of Urology, Penn Presbyterian Medical Center, Philadelphia, PA, USA., Lee D; Department of Urology, Penn Presbyterian Medical Center, Philadelphia, PA, USA., Yamoah K; Moffitt Cancer Center, Department of Radiation Oncology, University of South Florida, Tampa, FL, USA., Rebbeck TR; T.H. Chan School of Public Health and Dana Farber Cancer Institute, Harvard University, Boston, MA, USA., Khani F; Departments of Pathology and Laboratory Medicine and Urology, Weill Cornell Medicine, New York, NY, USA., Robinson BD; Departments of Pathology and Laboratory Medicine and Urology, Weill Cornell Medicine, New York, NY, USA., Eklund L; Department of Pathology, University of Turku, Institute of Biomedicine and Turku University Hospital, Turku, Finland., Jambor I; Department of Pathology, University of Turku, Institute of Biomedicine and Turku University Hospital, Turku, Finland.; Department of Diagnostic Radiology, University of Turku, Turku, Finland., Merisaari H; Department of Pathology, University of Turku, Institute of Biomedicine and Turku University Hospital, Turku, Finland., Ettala O; Department of Urology, University of Turku, Institute of Biomedicine and Turku University Hospital, Turku, Finland., Taimen P; Department of Pathology, University of Turku, Institute of Biomedicine and Turku University Hospital, Turku, Finland., Aronen HJ; Department of Pathology, University of Turku, Institute of Biomedicine and Turku University Hospital, Turku, Finland.; Turku University Hospital, Medical Imaging Centre of Southwest Finland, Turku, Finland., Boström PJ; Department of Urology, University of Turku and Turku University Hospital, Turku, Finland., Tewari A; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Magi-Galluzzi C; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA., Klein E; Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH, USA., Purysko A; Cleveland Clinic, Imaging Institute, Section of Abdominal Imaging, Cleveland, OH, USA., Nc Shih N; Department of Pathology, University of Pennsylvania, Philadelphia, PA, USA., Feldman M; Department of Pathology, University of Pennsylvania, Philadelphia, PA, USA., Gupta S; Department of Urology, Case Western Reserve University, Cleveland, OH, USA.; Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH, USA., Lal P; Department of Pathology, University of Pennsylvania, Philadelphia, PA, USA., Madabhushi A; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. anant.madabhushi@case.edu.; Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH, USA. anant.madabhushi@case.edu.
Jazyk: angličtina
Zdroj: NPJ precision oncology [NPJ Precis Oncol] 2021 May 03; Vol. 5 (1), pp. 35. Date of Electronic Publication: 2021 May 03.
DOI: 10.1038/s41698-021-00174-3
Abstrakt: Existing tools for post-radical prostatectomy (RP) prostate cancer biochemical recurrence (BCR) prognosis rely on human pathologist-derived parameters such as tumor grade, with the resulting inter-reviewer variability. Genomic companion diagnostic tests such as Decipher tend to be tissue destructive, expensive, and not routinely available in most centers. We present a tissue non-destructive method for automated BCR prognosis, termed "Histotyping", that employs computational image analysis of morphologic patterns of prostate tissue from a single, routinely acquired hematoxylin and eosin slide. Patients from two institutions (n = 214) were used to train Histotyping for identifying high-risk patients based on six features of glandular morphology extracted from RP specimens. Histotyping was validated for post-RP BCR prognosis on a separate set of n = 675 patients from five institutions and compared against Decipher on n = 167 patients. Histotyping was prognostic of BCR in the validation set (p < 0.001, univariable hazard ratio [HR] = 2.83, 95% confidence interval [CI]: 2.03-3.93, concordance index [c-index] = 0.68, median years-to-BCR: 1.7). Histotyping was also prognostic in clinically stratified subsets, such as patients with Gleason grade group 3 (HR = 4.09) and negative surgical margins (HR = 3.26). Histotyping was prognostic independent of grade group, margin status, pathological stage, and preoperative prostate-specific antigen (PSA) (multivariable p < 0.001, HR = 2.09, 95% CI: 1.40-3.10, n = 648). The combination of Histotyping, grade group, and preoperative PSA outperformed Decipher (c-index = 0.75 vs. 0.70, n = 167). These results suggest that a prognostic classifier for prostate cancer based on digital images could serve as an alternative or complement to molecular-based companion diagnostic tests.
Databáze: MEDLINE